Entrada Therapeutics to Present at Upcoming Investor Conferences
August 29 2023 - 7:00AM
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical
company aiming to transform the lives of patients by establishing
intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new
class of medicines, today announced the Company will participate in
two investor conferences in September.
Wells Fargo 2023 Healthcare
Conference Dipal Doshi, President and Chief Executive
Officer, will join an in person fireside chat on Thursday,
September 7, 2023 at 9:30 a.m. ET in Boston, MA.
H.C. Wainwright 25th
Annual Global Investment Conference Dipal Doshi,
President and Chief Executive Officer, will participate in a
virtual fireside chat at the conference taking place September
11-13, 2023. The presentation will be available to view beginning
on Monday, September 11, 2023 at 7:00 a.m. ET.
Live webcasts will be available on the Investor Relations
section of the Company’s website at www.entradatx.com. Replays will
be available on the Entrada website for 90 days following the
events.
About Entrada TherapeuticsEntrada Therapeutics
is a biopharmaceutical company aiming to transform the lives of
patients by establishing a new class of medicines, Endosomal Escape
Vehicle (EEV™)-therapeutics, to engage intracellular targets that
have long been considered inaccessible and undruggable. The
Company’s EEV therapeutics are designed to enable the efficient
intracellular delivery of a wide range of therapeutics into a
variety of organs and tissues, resulting in an improved therapeutic
index. Through its proprietary, highly versatile and modular EEV
platform, Entrada is building a robust development portfolio of
RNA-, antibody- and enzyme-based programs for the potential
treatment of neuromuscular, immunological, ocular and metabolic
diseases, among others. The Company’s lead oligonucleotide programs
include ENTR-601-44 and ENTR-601-45 for the potential treatment of
people living with Duchenne who are exon 44 and 45 skipping
amenable, respectively, as well as our partnered candidate ENTR-701
targeting myotonic dystrophy type 1 (DM1).
For more information about Entrada, please visit our
website, www.entradatx.com, and follow us
on LinkedIn.
Investor and Media ContactKarla MacDonaldChief
Corporate Affairs Officerkmacdonald@entradatx.com
Entrada Therapeutics (NASDAQ:TRDA)
Historical Stock Chart
From Apr 2024 to May 2024
Entrada Therapeutics (NASDAQ:TRDA)
Historical Stock Chart
From May 2023 to May 2024